U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H35F7N4O2.C4H4O4
Molecular Weight 744.6962
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ORVEPITANT MALEATE

SMILES

OC(=O)\C=C/C(O)=O.[H][C@@]12CCC(=O)N1CCN(C2)[C@H]3CCN([C@H](C3)C4=CC=C(F)C=C4C)C(=O)N(C)[C@H](C)C5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F

InChI

InChIKey=IPACOHTZCSBGBV-WUXDIRCFSA-N
InChI=1S/C31H35F7N4O2.C4H4O4/c1-18-12-23(32)4-6-26(18)27-16-24(40-10-11-41-25(17-40)5-7-28(41)43)8-9-42(27)29(44)39(3)19(2)20-13-21(30(33,34)35)15-22(14-20)31(36,37)38;5-3(6)1-2-4(7)8/h4,6,12-15,19,24-25,27H,5,7-11,16-17H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t19-,24+,25+,27-;/m1./s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/23539641 | https://en.wikipedia.org/wiki/Orvepitant | http://adisinsight.springer.com/drugs/800020168 | https://www.ncbi.nlm.nih.gov/pubmed/24075145

Orvepitant is a novel generation brain penetrant, selective and potent, small molecule NK-1 receptor antagonist. Orvepitant’s (GW823296) mode of action and developability characteristics made it a suitable development candidate for the treatment of common anxiety disorders, posttraumatic stress disorder and major depressive disorder. It’s in phase II clinical trials as an effective inhibitor of itch-associated response.

Originator

Curator's Comment: https://www.google.com/patents/EP2297152A1

Approval Year

TargetsConditions
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day multiple, oral (unknown)
Highest studied dose,Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy
n = 16
Health Status: unhealthy
Condition: cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 16
Sources:
Other AEs: Hyperhidrosis, Asthenia...
Other AEs:
Hyperhidrosis (moderate, 6.3%)
Asthenia (mild, 6.3%)
Dry mouth (mild, 6.3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Asthenia mild, 6.3%
30 mg 1 times / day multiple, oral (unknown)
Highest studied dose,Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy
n = 16
Health Status: unhealthy
Condition: cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 16
Sources:
Dry mouth mild, 6.3%
30 mg 1 times / day multiple, oral (unknown)
Highest studied dose,Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy
n = 16
Health Status: unhealthy
Condition: cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 16
Sources:
Hyperhidrosis moderate, 6.3%
30 mg 1 times / day multiple, oral (unknown)
Highest studied dose,Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy
n = 16
Health Status: unhealthy
Condition: cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 16
Sources:
PubMed

PubMed

TitleDatePubMed
Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies.
2013 May
Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
2013 Nov 1
Neurokinin-1 receptor antagonist orvepitant is an effective inhibitor of itch-associated response in a Mongolian gerbil model of scratching behaviour.
2014 Nov
Patents

Sample Use Guides

10 mg/day, 20 mg/day and 30 mg/day
Route of Administration: Oral
Orvepitant (0.3–10 nM) pre-incubated for 1 h at 37 C before adding the agonist substance P produced a non-surmountable antagonism of agonist CRC with apparent pKB values of 10.30 ± 0.30 (n = 4).
Name Type Language
ORVEPITANT MALEATE
USAN  
USAN  
Official Name English
1-PIPERIDINECARBOXAMIDE, N-((1R)-1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHYL)-2-(4-FLUORO-2-METHYLPHENYL)-4-((8AS)-HEXAHYDRO-6-OXOPYRROLO(1,2-A)PYRAZIN-2(1H)-YL)-N-METHYL-, (2R,4S)-, (2Z)-2-BUTENEDIOATE (1:1)
Common Name English
GW823296B
Code English
GW-823296B
Code English
(2R,4S)-N-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4-[(8aS)-6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]piperidine-1-carboxamide hydrogen mono[(2Z)-but-2-enedioate]
Common Name English
ORVEPITANT MALEATE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Fri Dec 15 17:28:21 GMT 2023 , Edited by admin on Fri Dec 15 17:28:21 GMT 2023
NCI_THESAURUS C28197
Created by admin on Fri Dec 15 17:28:21 GMT 2023 , Edited by admin on Fri Dec 15 17:28:21 GMT 2023
Code System Code Type Description
PUBCHEM
44225656
Created by admin on Fri Dec 15 17:28:21 GMT 2023 , Edited by admin on Fri Dec 15 17:28:21 GMT 2023
PRIMARY
FDA UNII
HAX0H28B6W
Created by admin on Fri Dec 15 17:28:21 GMT 2023 , Edited by admin on Fri Dec 15 17:28:21 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105667
Created by admin on Fri Dec 15 17:28:21 GMT 2023 , Edited by admin on Fri Dec 15 17:28:21 GMT 2023
PRIMARY
SMS_ID
300000041370
Created by admin on Fri Dec 15 17:28:21 GMT 2023 , Edited by admin on Fri Dec 15 17:28:21 GMT 2023
PRIMARY
USAN
GW-128
Created by admin on Fri Dec 15 17:28:21 GMT 2023 , Edited by admin on Fri Dec 15 17:28:21 GMT 2023
PRIMARY
NCI_THESAURUS
C90614
Created by admin on Fri Dec 15 17:28:21 GMT 2023 , Edited by admin on Fri Dec 15 17:28:21 GMT 2023
PRIMARY
CAS
579475-24-4
Created by admin on Fri Dec 15 17:28:21 GMT 2023 , Edited by admin on Fri Dec 15 17:28:21 GMT 2023
PRIMARY